A securities class action has been filed in the USDC – S.D.IN. against Integer Holdings Corporation (ITGR) (“Integer” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired Integer common stock between July 25, 2025, and October 22, 2025, both dates inclusive (the “Class Period”).
Integer is a leading global medical device contract manufacturer specializing in cardiac rhythm management and cardiovascular products. The Company’s Cardio & Vascular (“C&V”) segment contributes roughly 60% of Integer’s revenue and includes electrophysiology (“EP”) devices that map the heart’s electrical activity to diagnose and treat arrhythmias.
The Complaint alleges that, during the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose that:
(1) Integer materially overstated its competitive position within the growing EP manufacturing market;
(2) despite Integer’s claims of strong visibility into customer demand, the Company was experiencing a sustained deterioration in sales relating to two of its EP devices;
(3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for the Company’s C&V segment;
(4) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Integer common stock fell $35.22 per share, or more than 32%, to a closing price of $73.89 per share on October 23, 2025.
If you purchased Integer common stock during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.